Screener
Ligand Pharmaceuticals LGND EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Ligand Pharmaceuticals’s reported figures.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's EBITDA?
- Ligand Pharmaceuticals (LGND) reported EBITDA of $16.81M in Q2 2026.
- How has Ligand Pharmaceuticals's EBITDA changed year-over-year?
- Ligand Pharmaceuticals's EBITDA decreased by 0.9% year-over-year, from $16.97M to $16.81M.
- What is the long-term trend for Ligand Pharmaceuticals's EBITDA?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's EBITDA has grown at a -16.6% compound annual growth rate (CAGR), from $154.92M to $74.78M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Ligand Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude